<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vernal keratoconjunctivitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vernal keratoconjunctivitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Vernal keratoconjunctivitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pedram Hamrah, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reza Dana, MD, MPH, MSc</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Wood, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah S Jacobs, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>There are five main types of ocular allergy: seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis (GPC). VKC and AKC are chronic, bilateral, and severe forms of allergic inflammation affecting the ocular surface. These two relatively uncommon types of allergic eye disease can cause severe damage to the ocular surface, leading to corneal scarring and vision loss if not treated properly (this occurs more commonly with AKC than VKC). Type I hypersensitivity reactions are important in these diseases, although they are not the only pathophysiologic mechanism. VKC is reviewed in this topic. AKC is discussed separately. (See  <a class="medical medical_review" href="/d/html/5550.html" rel="external">"Atopic keratoconjunctivitis"</a>.)</p><p>GPC is an inflammatory disorder that represents a reaction to lid movement over a foreign substance, such as hard contact lenses. Toxic conjunctivitis is not allergic in nature, but it is frequently confused with allergic ocular disease. It develops with protracted use of topical medications, mostly due to preservatives. GPC and toxic conjunctivitis are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5553.html" rel="external">"Giant papillary conjunctivitis"</a> and  <a class="medical medical_review" href="/d/html/5555.html" rel="external">"Toxic conjunctivitis"</a>.)</p><p>Seasonal and perennial allergic conjunctivitis, the most common forms of ocular allergy, are also discussed separately. (See  <a class="medical medical_review" href="/d/html/5547.html" rel="external">"Allergic conjunctivitis: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>VKC most commonly occurs in boys living in warm, dry, subtropical climates, such as the Mediterranean, the Middle East, Central and West Africa, South America, and Asian countries, such as Japan, Thailand, and India [<a href="#rid1">1</a>]. The limbal form of VKC is seen most often in dark-skinned individuals from Africa and India. VKC is generally rare in cooler climates, such as Northern Europe and the temperate areas of North America. In the past, prevalence in these regions has been approximately 0.03 percent of the population. As an example, prevalence for Western Europe was 3.2 in 10,000, whereas a higher prevalence ranging from 2.4 to 27.8 in 10,000 was seen in Italy, a country with a Mediterranean climate [<a href="#rid2">2</a>]. However, the prevalence in cooler regions has increased, probably due to immigration of individuals from susceptible populations [<a href="#rid3">3</a>].</p><p>Males are more commonly affected than females. In one series, the male-to-female ratio was 3.2:1 in patients &lt;20 years of age but was nearly equal in older patients [<a href="#rid4">4</a>]. Age at onset is generally before 10 years, with the earliest reported onset at five months of age [<a href="#rid5">5</a>], although VKC can infrequently occur in adults. Patients usually "outgrow" the disease with the onset of puberty.</p><p>VKC is associated with other atopic manifestations in approximately one-half of patients; however, atopy is not necessarily related to the underlying pathogenesis of this condition [<a href="#rid4">4,6</a>]. The most common concomitant atopic diseases are asthma and allergic rhinitis. Aeroallergen sensitization by skin prick testing or allergen-specific immunoassay was reported in over 50 percent of patients in one study [<a href="#rid4">4</a>]. A family history of atopy was also reported in approximately one-half of patients in two studies [<a href="#rid4">4,7</a>]. In another study, atopy was more common in patients with the palpebral or tarsal form of the disease compared with the limbal form [<a href="#rid8">8</a>]. VKC was associated with a family history of other inflammatory diseases, such as psoriasis and thyroiditis, in one series [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The exact pathogenic mechanisms of VKC are not fully elucidated. Classic immunoglobulin E (IgE) mediated hypersensitivity and T helper cell type 2 (Th2) mediated responses are thought to play a major role [<a href="#rid6">6,9-11</a>], but other mechanisms may be involved, including immunoglobulin G (IgG) mediated responses, basophil hypersensitivity, and cellular delayed-type hypersensitivity.</p><p>Evidence supporting an atopic origin for VKC includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Seasonal incidence</p><p class="bulletIndent1"><span class="glyph">●</span>Increased number of eosinophils and mast cells in conjunctival specimens</p><p class="bulletIndent1"><span class="glyph">●</span>High levels of IgE in serum and tears</p><p class="bulletIndent1"><span class="glyph">●</span>Increased levels of mediators derived from mast cells and eosinophils, including histamine and tryptase, in tears</p><p class="bulletIndent1"><span class="glyph">●</span>Therapeutic response to mast cell stabilizers</p><p></p><p>Conjunctival accumulation of Th2 CD4+ cells may give rise to hyperreactivity against substances that commonly contact the conjunctiva. Offending allergens include pollens, dust mites, molds, and animal epithelium [<a href="#rid8">8,12,13</a>]. Nonspecific stimuli, such as wind, sunlight, and heat, also probably play a role [<a href="#rid14">14,15</a>].</p><p>Mast cells play a key role in the development of IgE-mediated reactions. In addition, they release inflammatory mediators (eg, histamine, interleukins) [<a href="#rid16">16-18</a>] that stimulate fibroblast activity and production of collagens I and III, resulting in the typical formation of giant papillae in VKC [<a href="#rid19">19</a>]. Furthermore, there is increased expression of histamine receptors (H<sub>1</sub>, H<sub>2</sub>, and H<sub>4</sub> receptors) in conjunctival tissue [<a href="#rid20">20</a>]. The necessary vascular supply of the forming giant papillae is provided by capillary proliferation. Chronic conjunctival inflammation in VKC is associated with increased staining via immunohistochemistry for mediators that may stimulate vascular proliferation [<a href="#rid21">21</a>].</p><p>Histologic analysis of ocular tissue reveals proliferative changes in the epithelium, hyperplasia of connective tissue, and cellular infiltration of the substantia propria [<a href="#rid4">4,19</a>]. The inflammatory infiltrate includes eosinophils, neutrophils, basophils, lymphocytes, plasma cells, mast cells, and fibroblasts. Conjunctival scrapings of VKC patients show a predominance of eosinophils, while basophils, neutrophils, and lymphocytes are rare. Increased numbers of mast cells, eosinophils, and lymphocytes are seen in conjunctival biopsies. Cytologic examination of mucus secretions reveals a predominance of eosinophils [<a href="#rid22">22-24</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3512395025"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Almost all patients with VKC note ocular pruritus [<a href="#rid1">1,4</a>].</p><p>Other symptoms of VKC include (in approximate order of frequency from high to low, although the frequency of each is highly variable):</p><p class="bulletIndent1"><span class="glyph">●</span>Photophobia</p><p class="bulletIndent1"><span class="glyph">●</span>Thick mucus discharge</p><p class="bulletIndent1"><span class="glyph">●</span>Tearing</p><p class="bulletIndent1"><span class="glyph">●</span>Burning</p><p class="bulletIndent1"><span class="glyph">●</span>Foreign body sensation</p><p class="bulletIndent1"><span class="glyph">●</span>Pain</p><p class="bulletIndent1"><span class="glyph">●</span>Blurred vision</p><p></p><p>VKC is named as such because severe symptoms most commonly occur in the spring (hence "vernal"), at least in the first few years of the disease. In one series of 195 patients in Italy, over three-quarters of patients had seasonal symptoms that began in March/April and resolved in September [<a href="#rid4">4</a>]. However, over one-fifth had chronic symptoms since disease onset, and an additional 16 percent of patients went on to have chronic symptoms after a seasonal presentation.</p><p class="headingAnchor" id="H5"><span class="h2">Signs</span><span class="headingEndMark"> — </span>Bilateral eye involvement and presence of giant cobblestone-like papillae on the upper tarsal conjunctiva (conjunctiva lining the upper eyelid) are nearly universal findings in patients with VKC (<a class="graphic graphic_picture graphicRef114194" href="/d/graphic/114194.html" rel="external">picture 1</a>) [<a href="#rid1">1,4</a>].</p><p>Other signs of VKC include (in approximate order of frequency from high to low, although the frequency of each is highly variable):</p><p class="bulletIndent1"><span class="glyph">●</span>Conjunctival and episcleral hyperemia</p><p class="bulletIndent1"><span class="glyph">●</span>Superficial keratopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Sticky, nonpurulent mucus discharge</p><p class="bulletIndent1"><span class="glyph">●</span>Horner-Trantas dots (<a class="graphic graphic_picture graphicRef119597" href="/d/graphic/119597.html" rel="external">picture 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Corneal shield ulcers</p><p class="bulletIndent1"><span class="glyph">●</span>Ptosis</p><p class="bulletIndent1"><span class="glyph">●</span>Blepharospasm</p><p></p><p>Examination of VKC patients may reveal a predominance of upper tarsal signs (palpebral VKC), limbal signs (limbal VKC), or a combination thereof:</p><p class="bulletIndent1"><span class="glyph">●</span>The tarsal or palpebral form involves the part of the conjunctiva that covers the inside of the eyelid (tarsus). Upper tarsal papillae are discrete, enlarged (&gt;1 mm), and give rise to a classic "cobblestone" appearance with flattened tops (<a class="graphic graphic_picture graphicRef76654" href="/d/graphic/76654.html" rel="external">picture 3</a>). Subepithelial fibrosis resulting from papillae hypertrophy can cause increased eyelid thickening and ptosis. Thick, ropy mucus secretions are usually present and associated with tarsal papillae. The skin or lid margins are rarely involved, and the cornea is also typically not involved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The limbal form involves the limbus of the eye, the thin border between the cornea and the sclera. Gelatinous, confluent, yellow-gray infiltrates (Horner-Trantas dots) are pathognomonic of the limbal form of the disease (<a class="graphic graphic_picture graphicRef53133" href="/d/graphic/53133.html" rel="external">picture 4</a>). Punctate collections of epithelial cells, eosinophils, and calcified corneal concretions may also be observed. Other corneal signs, which may also be sight threatening, include superficial peripheral neovascularization, punctate corneal epitheliopathy, shield ulcers, subepithelial scarring, and plaque formation secondary to accumulation of inflammatory debris. Shield ulcers are usually found in the upper half of the visual axis (<a class="graphic graphic_picture graphicRef64926" href="/d/graphic/64926.html" rel="external">picture 5</a>). After resolution, the ulcerated area leaves a ring-like scar.</p><p></p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>There are no established diagnostic criteria for VKC. The diagnosis of VKC is based upon the typical epidemiology and clinical features of VKC (eg, young boys living in warm climates who present with ocular pruritus and giant papillae on the conjunctival lining of the upper eyelid). A clinical grading system was proposed to aid in the diagnosis and management of VKC (<a class="graphic graphic_table graphicRef113816" href="/d/graphic/113816.html" rel="external">table 1</a>) [<a href="#rid25">25,26</a>]. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Clinical manifestations'</a> above and <a class="local">'Signs'</a> above.)</p><p class="headingAnchor" id="H8"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The main disease to consider in the differential diagnosis is atopic keratoconjunctivitis (AKC). However, in contrast to VKC, AKC is perennial from the outset, affects predominantly the lower tarsus (eyelid), and commonly presents with vision-threatening corneal scars and neovascularization.</p><p class="headingAnchor" id="H9"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H3210900611"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Therapy for VKC is long term and requires frequent follow-up. The management approach includes both pharmacologic and nonpharmacologic therapies (<a class="graphic graphic_algorithm graphicRef114080" href="/d/graphic/114080.html" rel="external">algorithm 1</a>) [<a href="#rid27">27</a>].</p><p>Topical antihistamines and mast cell stabilizers are first-line pharmacologic therapies. Treatment with topical corticosteroids is best undertaken by an ophthalmologist. Patients who do not respond to these therapies may benefit from an allergy evaluation and possibly allergen immunotherapy. Additional medications that may be effective in some patients include calcineurin inhibitors, nonsteroidal antiinflammatory drugs (NSAIDs), and oral antihistamines.</p><p>A proposed grading system may aid in choice of treatment (<a class="graphic graphic_table graphicRef113816" href="/d/graphic/113816.html" rel="external">table 1</a>) [<a href="#rid26">26</a>].</p><p>Treatment of underlying conditions, such as blepharitis, is also necessary for successful management of VKC. (See  <a class="medical medical_review" href="/d/html/6915.html" rel="external">"Blepharitis"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Basic eye care and avoidance of triggers</span><span class="headingEndMark"> — </span>All patients should be counseled in basic eye care and trigger avoidance (<a class="graphic graphic_algorithm graphicRef114080" href="/d/graphic/114080.html" rel="external">algorithm 1</a>). These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of nonspecific triggers, such as wind, heat, salt water, and sunlight whenever possible</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of exposure to known aeroallergens in patients with IgE-mediated disease (this can be challenging as patients with VKC can react to multiple aeroallergens)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of eye rubbing as it leads to a mechanical mast-cell degranulation, as well as exacerbation of the allergic process</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">Artificial tears</a>, especially in patients who develop tear film insufficiency due to the anticholinergic effect of systemic antihistamines</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cool compresses</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Initial topical therapy</span><span class="headingEndMark"> — </span>We suggest a topical dual-acting mast cell stabilizer and antihistamine as first-line therapy (<a class="graphic graphic_algorithm graphicRef114080" href="/d/graphic/114080.html" rel="external">algorithm 1</a>). Alternatives are a combination of a separate topical mast cell stabilizer and a topical antihistamine or a mast cell stabilizer alone. These agents should be used on a daily basis throughout the affected season (usually just the spring, but symptoms may extend into other seasons depending upon levels of pollen allergens and may occur nearly year round). If a dual-acting agent is not an option, alternatives are a combination of a separate topical mast cell stabilizer and a topical antihistamine or a mast cell stabilizer alone. However, the dual agents were more effective than mast cell stabilizers alone in studies using a conjunctival allergen challenge model [<a href="#rid28">28-33</a>]. Topical antihistamines alone are minimally effective for VKC and are not used as monotherapy.</p><p>Dual-acting agents have two main actions. As mast cell stabilizers, they inhibit mast cell degranulation, which is the first step in the allergic cascade. They also inhibit leukocyte activity and dampen mediator release from mast cells, basophils, eosinophils, and neutrophils. As antihistamines, they competitively and reversibly block histamine receptors in the conjunctiva and eyelids, thereby blocking the actions of the primary mast cell-derived mediator [<a href="#rid34">34</a>]. This also helps reduce the late phase of the allergic response.</p><p>Dual-acting agents include <a class="drug drug_general" data-topicid="10177" href="/d/drug information/10177.html" rel="external">olopatadine</a>, <a class="drug drug_general" data-topicid="8798" href="/d/drug information/8798.html" rel="external">azelastine</a> hydrochloride, <a class="drug drug_general" data-topicid="8601" href="/d/drug information/8601.html" rel="external">epinastine</a>, pemirolast potassium, and <a class="drug drug_general" data-topicid="16764" href="/d/drug information/16764.html" rel="external">ketotifen</a> fumarate (this last option is available in a generic formulation and is over the counter in the United States). These drugs have been studied extensively in seasonal and perennial allergic conjunctivitis [<a href="#rid35">35-37</a>]. However, there are only a few nonrandomized studies on use of these drugs, specifically olopatadine and ketotifen, in patients with VKC [<a href="#rid33">33,38</a>]. Common side effects of these medications include stinging upon instillation and headache. (See  <a class="medical medical_review" href="/d/html/90512.html" rel="external">"Allergic conjunctivitis: Management"</a>.)</p><p>In one observational study, topical <a class="drug drug_general" data-topicid="10177" href="/d/drug information/10177.html" rel="external">olopatadine</a> hydrochloride 0.1% significantly decreased most signs and symptoms of VKC, including itching, tearing, burning, mucus discharge, conjunctival hyperemia, and corneal involvement after two months of therapy [<a href="#rid33">33</a>]. However, photophobia and limbal papillae did not improve significantly. In another observational study, patients treated with <a class="drug drug_general" data-topicid="16764" href="/d/drug information/16764.html" rel="external">ketotifen</a> had greater improvement in itching, tearing, conjunctival hyperemia, mucus discharge, and photophobia after three weeks of therapy than patients treated with olopatadine [<a href="#rid38">38</a>].</p><p>Topical mast cell stabilizers include <a class="drug drug_general" data-topicid="9300" href="/d/drug information/9300.html" rel="external">cromolyn</a> sodium [<a href="#rid39">39</a>], <a class="drug drug_general" data-topicid="9987" href="/d/drug information/9987.html" rel="external">nedocromil</a> sodium [<a href="#rid40">40,41</a>], and <a class="drug drug_general" data-topicid="9567" href="/d/drug information/9567.html" rel="external">lodoxamide</a> [<a href="#rid42">42,43</a>]. Mast cell stabilizers have repeatedly been shown to be effective in patients with VKC [<a href="#rid39">39-43</a>]. A systematic review and meta-analysis of these agents showed that all resulted in significant improvement in signs and symptoms of VKC, with the exception of photophobia [<a href="#rid44">44</a>]. Comparison of the efficacy of the different drugs was not possible due to variability in the study designs. Mast cell stabilizers have no effect on mediators once they are released but are effective in preventing mast cell degranulation. The onset of action of these drugs is 5 to 14 days after initiation of therapy. Thus, these drugs are <strong>not</strong> useful for acute symptoms. In addition, dosing of mast cell stabilizers is three to four times daily compared with twice daily for most agents with combined actions. These features may limit patient compliance.</p><p class="headingAnchor" id="H3435921113"><span class="h2">Add-on initial therapy for moderate-to-severe disease</span><span class="headingEndMark"> — </span>There is no widely accepted grading scheme for VKC. In general, the condition is considered severe when it affects vision or leads to symptoms of itch and irritation most of the time. Patients with mild-to-moderate disease have intermittent symptoms (more frequent in the moderate group but not nearly continuous as with severe disease) and no visual deficits. We suggest adding a second- or third-generation oral antihistamine in patients with moderate-to-severe disease. Oral antihistamines, including <a class="drug drug_general" data-topicid="8445" href="/d/drug information/8445.html" rel="external">fexofenadine</a>, <a class="drug drug_general" data-topicid="9572" href="/d/drug information/9572.html" rel="external">loratadine</a>, <a class="drug drug_general" data-topicid="8472" href="/d/drug information/8472.html" rel="external">desloratadine</a>, <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a>, and <a class="drug drug_general" data-topicid="9443" href="/d/drug information/9443.html" rel="external">levocetirizine</a>, have demonstrated efficacy in the treatment of allergic conjunctivitis but have not been well studied in patients with VKC [<a href="#rid45">45</a>]. These agents have a slower onset of action compared with topical agents (one-half to two hours rather than a few minutes). Maximizing the dose of nonsedating antihistamine will often improve efficacy. (See  <a class="medical medical_review" href="/d/html/90512.html" rel="external">"Allergic conjunctivitis: Management"</a>.)</p><p>Oral antihistamine use may be associated with drying of mucosal membranes and decreased tear production in some patients, especially those with concomitant dry eye. This side effect can usually be countered with the liberal application of <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a>. <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">Cetirizine</a> causes sedation in a subset of patients, despite its categorization as nonsedating.</p><p class="headingAnchor" id="H3333240996"><span class="h2">Treatment of refractory disease</span><span class="headingEndMark"> — </span>For patients with VKC who fail to respond to two to three weeks of a dual-acting antihistamine/mast cell stabilizer (first confirming consistent use), we suggest a short-term, high-dose pulse regimen of topical corticosteroids, with referral to an ophthalmologist for management of this therapy (<a class="graphic graphic_algorithm graphicRef114080" href="/d/graphic/114080.html" rel="external">algorithm 1</a>). If control is not obtained after two to three weeks of topical corticosteroid therapy, we refer to an allergy specialist for possible allergen immunotherapy (VKC is unlikely if testing to aeroallergens is negative, and the patient should be evaluated for other causes of conjunctivitis). For patients with moderate-to-severe disease who require frequent or prolonged courses of topical corticosteroids and have trouble controlling symptoms when topical corticosteroids are reduced, we suggest using topical <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> 0.1% one drop each eye four times daily (can be increased to 2% one drop each eye two times daily in severe or unresponsive cases) as a corticosteroid-sparing agent. An alternative is topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>. A topical calcineurin inhibitor such as cyclosporine is used rather than topical corticosteroids if the corneal epithelium is compromised, particularly in the presence of shield ulcers (see <a class="local">'Treatment of corneal shield ulcers'</a> below). Several classes of medications may need to be used concurrently. Starting one does not mean others have to be terminated. In general, we recommend starting, stopping, and tapering medication based upon the patient's symptoms. Most patients have adequate control with these measures over time, but a small percentage require systemic immunosuppressive therapy (eg, cyclosporine). Systemic glucocorticoids are not used for VKC.</p><p class="headingAnchor" id="H12"><span class="h3">Topical corticosteroids</span><span class="headingEndMark"> — </span>A short-term, high-dose pulse regimen of topical corticosteroids is often necessary in patients with VKC who fail to respond to two to three weeks of a dual-acting antihistamine/mast cell stabilizer, particularly those with significant seasonal exacerbations. Close follow-up with an ophthalmologist is required due to vision-threatening side effects of topical corticosteroids, such as glaucoma, cataracts, and secondary infections. Patients should know that blindness is a risk of unsupervised topical corticosteroid therapy. Topical corticosteroids are not used if the corneal epithelium is compromised. (See <a class="local">'Treatment of corneal shield ulcers'</a> below.)</p><p>In severe cases of VKC, <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> acetate 1% eight times daily for one week leads to significant symptom relief and thereafter should be tapered rapidly once control is gained [<a href="#rid46">46</a>]. In less severe cases, pulse therapy with topical "soft" steroids on a two to four times per day basis for approximately two weeks is effective in gaining control of the allergic response so that mast cell stabilizers, antihistamines, and <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> have a greater chance to work [<a href="#rid40">40,47</a>]. Use of topical "soft" corticosteroids for greater than six weeks is associated with a significantly increased risk of complications.</p><p><a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">Prednisolone</a> acetate 1% and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 0.1% have the greatest efficacy/potency but also the greatest risk of raising intraocular pressure (IOP) among all topical corticosteroids. By comparison, "soft" steroids are a group of topical corticosteroids that have a greatly reduced risk of causing increased IOP because they bind with high affinity to the glucocorticoid receptor and the unbound drug undergoes rapid inactivation upon penetration of the cornea. Topical "soft" corticosteroids include prednisolone acetate 0.12%, <a class="drug drug_general" data-topicid="8463" href="/d/drug information/8463.html" rel="external">fluorometholone</a>, medrysone, <a class="drug drug_general" data-topicid="10116" href="/d/drug information/10116.html" rel="external">loteprednol</a> etabonate 0.5 or 0.2%, and <a class="drug drug_general" data-topicid="9867" href="/d/drug information/9867.html" rel="external">rimexolone</a> 1%.</p><p>Observational studies and one randomized trial have shown that topical corticosteroids are effective in treating VKC [<a href="#rid4">4,40,47</a>]. In the small, randomized trial, a two-week course of <a class="drug drug_general" data-topicid="8463" href="/d/drug information/8463.html" rel="external">fluorometholone</a> 0.1% was more effective than <a class="drug drug_general" data-topicid="9987" href="/d/drug information/9987.html" rel="external">nedocromil</a> 2% in decreasing signs and symptoms of VKC, including papillary hypertrophy, Horner-Trantas dots, mucus discharge, conjunctival hyperemia, and tearing [<a href="#rid40">40</a>].</p><p>Corticosteroids suppress the late-phase reaction in both experimental and clinical settings. These drugs, in part, limit the inflammatory cascade by inhibiting phospholipase A2. Consequently, they reduce the formation of lipid-derived mediators from arachidonic acid, which prevents leukocyte migration, hydrolytic enzyme release, fibroblast growth, and changes in vascular permeability.</p><p class="headingAnchor" id="H13"><span class="h3">Allergen immunotherapy</span><span class="headingEndMark"> — </span>Patients should be referred to an allergy specialist for consideration of allergen immunotherapy if control is not obtained with topical corticosteroids after two to three weeks of therapy [<a href="#rid48">48</a>]. The indications for and efficacy of allergen immunotherapy are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/361.html" rel="external">"Subcutaneous immunotherapy (SCIT) for allergic rhinoconjunctivitis and asthma: Indications and efficacy"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Calcineurin inhibitors</span><span class="headingEndMark"> — </span>The calcineurin inhibitors that are most commonly used in ocular allergy include topical <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> and systemic cyclosporine. An important advantage of the topical calcineurin inhibitors is that they do not cause the same side effects typically seen with topical corticosteroids, such as an increase in IOP. Thus, long-term use of these agents is considered safe when used topically, unlike chronic use of topical corticosteroids, and only minimal amounts can be traced systemically. However, topical cyclosporine and tacrolimus are generally not chosen over topical corticosteroids for acute exacerbations, because of their much slower onset of action (weeks to a couple of months rather than hours to days). Systemic cyclosporine is reserved for corticosteroid-dependent patients who do not respond to other therapies.</p><p><a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">Cyclosporine</a> diminishes the effect of interleukin (IL) 2 on T cells and leads to decreased expansion of T helper cells. It may also inhibit mast cell proliferation and survival. Cyclosporine reduces collagen production and induces apoptosis of conjunctival fibroblasts from VKC patients. <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">Tacrolimus</a> has similar mechanisms of action [<a href="#rid49">49,50</a>]. Efficacy of topical cyclosporine and topical tacrolimus was similar (symptom and sign score -2.06 and -2.39, respectively) in a meta-analysis of VKC therapies [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H2912421878"><span class="h4">Topical cyclosporine</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> 2% emulsion improved signs and symptoms of VKC in several small, randomized trials [<a href="#rid52">52,53</a>] and observational studies [<a href="#rid54">54-57</a>]. Both randomized trials demonstrated a significant improvement in symptoms (eg, itching, tearing, mucus discharge) and signs (papillary hypertrophy, conjunctival hyperemia, Horner-Trantas dots) compared with placebo [<a href="#rid52">52,53</a>]. However, 4 of 24 patients in one of the trials required a brief course of topical corticosteroids during the four-month study period [<a href="#rid53">53</a>]. In one study, topical cyclosporine 0.1% was less effective than topical <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 0.15% for acute flare ups, with less improvement in symptoms and signs and a greater number of patients requiring rescue therapy with topical dexamethasone [<a href="#rid58">58</a>]. In two subsequent randomized trials, topical cyclosporine emulsion 0.1% four times daily was more effective than cyclosporine emulsion 0.1% twice daily, cyclosporine emulsion 0.05% four times daily, and placebo for both corneal <a class="drug drug_general" data-topicid="8461" href="/d/drug information/8461.html" rel="external">fluorescein</a> staining and itching [<a href="#rid59">59,60</a>].</p><p class="headingAnchor" id="H2680846025"><span class="h4">Topical tacrolimus</span><span class="headingEndMark"> — </span>Efficacy of topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> in patients with VKC was demonstrated in small, observational studies [<a href="#rid49">49,50</a>] and randomized trials [<a href="#rid61">61-66</a>]. While topical tacrolimus and topical <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> have similar efficacy, topical tacrolimus is more likely to cause a burning sensation, which impacts adherence and limits use [<a href="#rid51">51</a>]. Several randomized trials demonstrated a significant improvement in symptoms and signs with tacrolimus treatment. In two randomized trials comparing cyclosporine with 0.1% tacrolimus, patients achieved similar statistically significant improvement in both signs and symptoms [<a href="#rid61">61,62</a>]. In another trial, tacrolimus 0.03% resulted in similar improvement in signs and symptoms as compared with tacrolimus with 1% <a class="drug drug_general" data-topicid="10177" href="/d/drug information/10177.html" rel="external">olopatadine</a> [<a href="#rid63">63</a>]. In yet another trial comparing 0.03% tacrolimus with 0.05% cyclosporine, patients in both groups demonstrated equal efficacy to both drugs [<a href="#rid64">64</a>]. However, tacrolimus 0.03% was more effective than sodium cromoglycate 4% in one trial [<a href="#rid65">65</a>]. In a subsequent trial, a lower concentration of 0.005% tacrolimus was as effective as interferon alpha-2b in improving both signs and symptoms [<a href="#rid66">66</a>]. Topical tacrolimus 0.1% was also shown to be effective in a double-blind crossover trial of 30 patients with severe VKC who failed to respond to topical cyclosporine [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H1376578477"><span class="h4">Systemic cyclosporine</span><span class="headingEndMark"> — </span>In the authors' clinical experience, systemic <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> can be helpful in controlling severe, corticosteroid-dependent cases of allergic ocular disease that have not responded to other therapy, thereby reducing the need for long-term corticosteroid use. However, no randomized trial has been performed evaluating the utility of systemic cyclosporine in the treatment of ocular allergy [<a href="#rid67">67</a>]. Systemic cyclosporine is generally limited to patients with severe atopic keratoconjunctivitis (AKC) who do not respond adequately to topical therapy; it would be extremely rare to use this therapeutic approach in VKC. If administered, oral dosing is 2.5 to 5 mg/kg per day during the affected season. The patient must be closely monitored for any adverse effects including kidney dysfunction, bone marrow suppression, hypertension, tremor, hirsutism, and gingival hyperplasia. Systemic cyclosporine is rarely, if ever, needed in VKC.</p><p class="headingAnchor" id="H3078223663"><span class="h2">Treatment for subsequent seasons</span><span class="headingEndMark"> — </span>In patients with known disease, a dual-acting agent should be started approximately a month before the usual onset of their seasonal symptoms and continued for the duration of the season. Dual-acting agents have a quick onset of action, but the start of the season can vary from year to year, and allergic responses, once activated, can last up to two months. Thus, it is better to start treatment a bit early to ensure that the mast cells are stabilized before the onset of the season. While mast cell stabilizers have a slower onset of action than dual-acting agents, starting one of these drugs a month before the usual onset of symptoms is usually sufficient. Topical <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, while effective, is typically not used as initial therapy for subsequent seasons, because it would need to be started even further in advance of the season due to its very slow onset of action [<a href="#rid58">58,68</a>]. The approach for patients who fail to respond to initial therapy in subsequent seasons is similar to that outlined above. Patients who are asymptomatic on just a dual-acting agent or mast cell stabilizer for a season can do a trial without therapy the following season to determine if the disease has resolved. (See <a class="local">'Add-on initial therapy for moderate-to-severe disease'</a> above and <a class="local">'Treatment of refractory disease'</a> above and <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H18"><span class="h2">Treatment of corneal shield ulcers</span><span class="headingEndMark"> — </span>Corneal shield ulcers are a vision-threatening complication of VKC. Topical <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> is used rather than topical corticosteroids if the corneal epithelium is compromised, particularly in the presence of shield ulcers, because topical corticosteroids have been shown to interfere with re-epithelialization. Additional therapy for sterile corneal ulcers includes debridement of inflammatory debris and the use of wide-spectrum antibiotics, such as <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> or <a class="drug drug_general" data-topicid="8928" href="/d/drug information/8928.html" rel="external">gatifloxacin</a> four times per day [<a href="#rid69">69-72</a>]. Patching, bandage contact lenses, and temporary tarsorrhaphy (upper and lower eyelids are partially sewn together) may be required to help the epithelial defects heal. Infectious ulcers should be referred promptly to the appropriate specialist due to the high likelihood of vision loss and the complexity of treatment.</p><p class="headingAnchor" id="H3998440023"><span class="h2">Additional agents</span><span class="headingEndMark"> — </span>Nonsteroidal antiinflammatory drugs (NSAIDs) have been studied in the treatment of VKC but are used rarely due to the availability of agents with greater efficacy. NSAIDs block the action of cyclooxygenase and thus inhibit the conversion of arachidonic acid to prostaglandins and thromboxanes. Topical NSAID preparations include <a class="drug drug_general" data-topicid="8591" href="/d/drug information/8591.html" rel="external">ketorolac</a> [<a href="#rid73">73,74</a>], <a class="drug drug_general" data-topicid="8668" href="/d/drug information/8668.html" rel="external">bromfenac</a> [<a href="#rid75">75</a>], <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> [<a href="#rid76">76</a>], <a class="drug drug_general" data-topicid="8470" href="/d/drug information/8470.html" rel="external">flurbiprofen</a> [<a href="#rid77">77</a>], and <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> [<a href="#rid78">78</a>]. Ketorolac was shown to be more effective in treating symptoms of VKC than placebo in one small, randomized trial [<a href="#rid73">73</a>] and had greater efficacy in treating symptoms, but not signs of VKC, than <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> 0.5% by day 7 in another randomized trial [<a href="#rid74">74</a>]. Flurbiprofen demonstrated lower efficacy compared with topical <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a> [<a href="#rid77">77</a>]. Indomethacin treatment showed mixed results for VKC [<a href="#rid78">78</a>].</p><p><a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">Omalizumab</a>, an anti-IgE monoclonal antibody, was shown to resolve ocular signs and symptoms of VKC in a series of four children despite negative blood and skin testing for environmental allergies [<a href="#rid79">79</a>]. Dosing was based upon weight and total IgE level using the same dosing schedule used for patients with asthma. Improvement was noted within the first few weeks of treatment, and none of the patients relapsed after treatment was discontinued after six months of therapy. These results are consistent with other case reports [<a href="#rid80">80-83</a>]. The exact mechanism that leads to clinical improvement in these patients is unclear, and further study is needed. (See  <a class="medical medical_review" href="/d/html/545.html" rel="external">"Anti-IgE therapy", section on 'Administration'</a>.)</p><p class="headingAnchor" id="H446200092"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Overall, most patients do well with treatment and only require seasonal therapy. Patients typically outgrow VKC, but it can take a number of years. Vision loss in VKC is rare but can occur due to corneal scarring, neovascularization, and amblyopia. A more severe baseline grade, a younger age of onset, and a higher rate of recurrences of ocular inflammation were all associated with a worse visual outcome in a series of 110 patients, suggesting that more aggressive treatment may be appropriate in these higher-risk patients [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H158431491"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109230.html" rel="external">"Society guideline links: Allergic eye disease"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Vernal keratoconjunctivitis (VKC) is a seasonally recurring, bilateral, and severe form of allergic inflammation affecting the ocular surface. This relatively uncommon type of allergic eye disease can cause severe damage to the ocular surface, leading to corneal scarring and vision loss if not treated properly. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VKC most commonly occurs in boys living in warm, dry, subtropical climates. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common manifestations of VKC are ocular pruritus and giant cobblestone-like papillae on the upper tarsal conjunctiva (<a class="graphic graphic_picture graphicRef76654" href="/d/graphic/76654.html" rel="external">picture 3</a>). (See <a class="local">'Clinical manifestations'</a> above and <a class="local">'Signs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of VKC is based upon the typical epidemiology and clinical features of VKC (eg, young boys living in warm climates who present with ocular pruritus and giant papillae on the conjunctival lining of the upper eyelid). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The management approach includes both nonpharmacologic measures (ie, basic eye care and trigger avoidance) and pharmacologic therapies (<a class="graphic graphic_algorithm graphicRef114080" href="/d/graphic/114080.html" rel="external">algorithm 1</a>). (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest a topical dual-acting mast cell stabilizer and antihistamine as first-line therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Alternatives are a combination of a separate topical mast cell stabilizer and a topical antihistamine or a mast cell stabilizer alone. We suggest adding a second- or third-generation oral antihistamine in patients with moderate-to-severe disease (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Initial topical therapy'</a> above and <a class="local">'Add-on initial therapy for moderate-to-severe disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest a short-term, high-dose pulse regimen of topical corticosteroids in patients with VKC who fail to respond to two to three weeks of a dual-acting antihistamine/mast cell stabilizer (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Close follow-up with an ophthalmologist is required due to vision-threatening side effects of topical corticosteroids, such as glaucoma, cataracts, and secondary infections. (See <a class="local">'Topical corticosteroids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest using topical <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> 0.1% one drop each eye four times daily as a corticosteroid-sparing agent in patients with moderate-to-severe disease who require frequent or prolonged courses of topical corticosteroids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The dose may be increased to 2% one drop each eye two times daily in severe or unresponsive cases. Topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> is an alternative to topic cyclosporine but is more likely to cause a burning sensation, which can impact adherence to treatment. (See <a class="local">'Calcineurin inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Corneal shield ulcers are a vision-threatening complication of VKC. Topical <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> is used rather than topical corticosteroids if the corneal epithelium is compromised, particularly in the presence of shield ulcers. Additional therapy is also required. (See <a class="local">'Treatment of corneal shield ulcers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vision loss in VKC is uncommon but can occur due to corneal scarring, neovascularization, and amblyopia. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kumar S. Vernal keratoconjunctivitis: a major review. Acta Ophthalmol 2009; 87:133.</a></li><li><a class="nounderline abstract_t">Bremond-Gignac D, Donadieu J, Leonardi A, et al. Prevalence of vernal keratoconjunctivitis: a rare disease? Br J Ophthalmol 2008; 92:1097.</a></li><li><a class="nounderline abstract_t">Montan PG, Ekström K, Hedlin G, et al. Vernal keratoconjunctivitis in a Stockholm ophthalmic centre--epidemiological, functional, and immunologic investigations. Acta Ophthalmol Scand 1999; 77:559.</a></li><li><a class="nounderline abstract_t">Bonini S, Bonini S, Lambiase A, et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology 2000; 107:1157.</a></li><li><a class="nounderline abstract_t">Ukponmwan CU. Vernal keratoconjunctivitis in Nigerians: 109 consecutive cases. Trop Doct 2003; 33:242.</a></li><li><a class="nounderline abstract_t">Lambiase A, Minchiotti S, Leonardi A, et al. Prospective, multicenter demographic and epidemiological study on vernal keratoconjunctivitis: a glimpse of ocular surface in Italian population. Ophthalmic Epidemiol 2009; 16:38.</a></li><li><a class="nounderline abstract_t">Tesse R, Spadavecchia L, Fanelli P, et al. New insights into childhood Vernal keratoconjunctivitis-associated factors. Pediatr Allergy Immunol 2012; 23:682.</a></li><li><a class="nounderline abstract_t">Tuft SJ, Dart JK, Kemeny M. Limbal vernal keratoconjunctivitis: clinical characteristics and immunoglobulin E expression compared with palpebral vernal. Eye (Lond) 1989; 3 ( Pt 4):420.</a></li><li><a class="nounderline abstract_t">Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res 2002; 21:319.</a></li><li><a class="nounderline abstract_t">Mantelli F, Lambiase A, Bonini S. A simple and rapid diagnostic algorithm for the detection of ocular allergic diseases. Curr Opin Allergy Clin Immunol 2009; 9:471.</a></li><li><a class="nounderline abstract_t">Offiah I, Calder VL. Immune mechanisms in allergic eye diseases: what is new? Curr Opin Allergy Clin Immunol 2009; 9:477.</a></li><li><a class="nounderline abstract_t">Mumcuoglu YK, Zavaro A, Samra Z, Lazarowitz Z. House dust mites and vernal keratoconjunctivitis. Ophthalmologica 1988; 196:175.</a></li><li><a class="nounderline abstract_t">Fujishima H, Saito I, Takeuchi T, Tsubota K. Immunological characteristics of patients with vernal keratoconjunctivitis. Jpn J Ophthalmol 2002; 46:244.</a></li><li><a class="nounderline abstract_t">Bonini S, Bonini S, Schiavone M, et al. Conjunctival hyperresponsiveness to ocular histamine challenge in patients with vernal conjunctivitis. J Allergy Clin Immunol 1992; 89:103.</a></li><li><a class="nounderline abstract_t">Pucci N, Novembre E, Lombardi E, et al. Long eyelashes in a case series of 93 children with vernal keratoconjunctivitis. Pediatrics 2005; 115:e86.</a></li><li><a class="nounderline abstract_t">Abelson MB, Baird RS, Allansmith MR. Tear histamine levels in vernal conjunctivitis and other ocular inflammations. Ophthalmology 1980; 87:812.</a></li><li><a class="nounderline abstract_t">Leonardi A, Fregona IA, Plebani M, et al. Th1- and Th2-type cytokines in chronic ocular allergy. Graefes Arch Clin Exp Ophthalmol 2006; 244:1240.</a></li><li><a class="nounderline abstract_t">Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy 2006; 36:777.</a></li><li><a class="nounderline abstract_t">Leonardi A, Abatangelo G, Cortivo R, Secchi AG. Collagen types I and III in giant papillae of vernal keratoconjunctivitis. Br J Ophthalmol 1995; 79:482.</a></li><li><a class="nounderline abstract_t">Leonardi A, Di Stefano A, Vicari C, et al. Histamine H4 receptors in normal conjunctiva and in vernal keratoconjunctivitis. Allergy 2011; 66:1360.</a></li><li><a class="nounderline abstract_t">Abu El-Asrar AM, Al-Mansouri S, Tabbara KF, et al. Immunopathogenesis of conjunctival remodelling in vernal keratoconjunctivitis. Eye (Lond) 2006; 20:71.</a></li><li><a class="nounderline abstract_t">Leonardi A, Jose PJ, Zhan H, Calder VL. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology 2003; 110:487.</a></li><li><a class="nounderline abstract_t">Kari O. Atopic conjunctivitis. A cytologic examination. Acta Ophthalmol (Copenh) 1988; 66:381.</a></li><li><a class="nounderline abstract_t">Tsubota K, Takamura E, Hasegawa T, Kobayashi T. Detection by brush cytology of mast cells and eosinophils in allergic and vernal conjunctivitis. Cornea 1991; 10:525.</a></li><li><a class="nounderline abstract_t">Bonini S, Sacchetti M, Mantelli F, Lambiase A. Clinical grading of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol 2007; 7:436.</a></li><li><a class="nounderline abstract_t">Sacchetti M, Lambiase A, Mantelli F, et al. Tailored approach to the treatment of vernal keratoconjunctivitis. Ophthalmology 2010; 117:1294.</a></li><li><a class="nounderline abstract_t">Kumar S, Gupta N, Vivian AJ. Modern approach to managing vernal keratoconjunctivitis. Curr Allergy Asthma Rep 2010; 10:155.</a></li><li><a class="nounderline abstract_t">Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 1998; 81:211.</a></li><li><a class="nounderline abstract_t">Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 1998; 125:797.</a></li><li><a class="nounderline abstract_t">Berdy GJ, Stoppel JO, Epstein AB. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin Ther 2002; 24:918.</a></li><li><a class="nounderline abstract_t">Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 2001; 23:1272.</a></li><li><a class="nounderline abstract_t">Uchio E. Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops. Clin Ophthalmol 2008; 2:525.</a></li><li><a class="nounderline abstract_t">Corum I, Yeniad B, Bilgin LK, Ilhan R. Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density. J Ocul Pharmacol Ther 2005; 21:400.</a></li><li class="breakAll">Abelson MB, Weston JH. Antihistamines. In: Clinical ophthalmic pharmacology, Lamberts DW, Potter DE (Eds), Little Brown, Boston 1987.</li><li><a class="nounderline abstract_t">Abelson MB, Gomes P, Crampton HJ, et al. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther 2004; 26:35.</a></li><li><a class="nounderline abstract_t">Gous P, Ropo A. A comparative trial of the safety and efficacy of 0.1 percent pemirolast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 2004; 20:139.</a></li><li><a class="nounderline abstract_t">Crampton HJ. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Clin Ther 2003; 25:1975.</a></li><li><a class="nounderline abstract_t">Hida WT, Nogueira DC, Schaefer A, et al. [Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis]. Arq Bras Oftalmol 2006; 69:851.</a></li><li><a class="nounderline abstract_t">Foster CS. Evaluation of topical cromolyn sodium in the treatment of vernal keratoconjunctivitis. Ophthalmology 1988; 95:194.</a></li><li><a class="nounderline abstract_t">Tabbara KF, al-Kharashi SA. Efficacy of nedocromil 2% versus fluorometholone 0.1%: a randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis. Br J Ophthalmol 1999; 83:180.</a></li><li><a class="nounderline abstract_t">Bonini S, Lambiase A, Matricardi P, et al. Atopic and vernal keratoconjunctivitis: a model for studying atopic disease. Curr Probl Dermatol 1999; 28:88.</a></li><li><a class="nounderline abstract_t">Avunduk AM, Avunduk MC, Kapicioglu Z, et al. Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis. Ophthalmology 2000; 107:1333.</a></li><li><a class="nounderline abstract_t">Leonardi A, Borghesan F, Avarello A, et al. Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis. Br J Ophthalmol 1997; 81:23.</a></li><li><a class="nounderline abstract_t">Mantelli F, Santos MS, Petitti T, et al. Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis. Br J Ophthalmol 2007; 91:1656.</a></li><li><a class="nounderline abstract_t">Alexander M. Comparative therapeutic studies with Tilavist. Allergy 1995; 50:23.</a></li><li><a class="nounderline abstract_t">Kosrirukvongs P, Vichyanond P, Wongsawad W. Vernal keratoconjunctivitis in Thailand. Asian Pac J Allergy Immunol 2003; 21:25.</a></li><li><a class="nounderline abstract_t">Bonini S, Coassin M, Aronni S, Lambiase A. Vernal keratoconjunctivitis. Eye (Lond) 2004; 18:345.</a></li><li><a class="nounderline abstract_t">López-Piedrahita E, Sánchez-Caraballo JM, Ramírez-Girado RH, Cardona-Villa R. [Effectiveness of allergen immunotherapy in patients with vernal keratoconjuctivitis]. Rev Alerg Mex 2013; 60:11.</a></li><li><a class="nounderline abstract_t">Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, et al. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 2008; 115:988.</a></li><li><a class="nounderline abstract_t">Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, et al. Vernal keratoconjunctivitis: Result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J Allergy Clin Immunol 2004; 113:355.</a></li><li><a class="nounderline abstract_t">Roumeau I, Coutu A, Navel V, et al. Efficacy of medical treatments for vernal keratoconjunctivitis: A systematic review and meta-analysis. J Allergy Clin Immunol 2021; 148:822.</a></li><li><a class="nounderline abstract_t">Bleik JH, Tabbara KF. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991; 98:1679.</a></li><li><a class="nounderline abstract_t">Pucci N, Novembre E, Cianferoni A, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 2002; 89:298.</a></li><li><a class="nounderline abstract_t">Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990; 110:641.</a></li><li><a class="nounderline abstract_t">Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea 1993; 12:413.</a></li><li><a class="nounderline abstract_t">Tomida I, Schlote T, Bräuning J, et al. [Cyclosporin A 2% eyedrops in therapy of atopic and vernal keratoconjunctivitis]. Ophthalmologe 2002; 99:761.</a></li><li><a class="nounderline abstract_t">Avunduk AM, Avunduk MC, Erdöl H, et al. Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis. Ophthalmologica 2001; 215:290.</a></li><li><a class="nounderline abstract_t">Lambiase A, Leonardi A, Sacchetti M, et al. Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study. J Allergy Clin Immunol 2011; 128:896.</a></li><li><a class="nounderline abstract_t">Leonardi A, Doan S, Amrane M, et al. A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis: The VEKTIS Study. Ophthalmology 2019; 126:671.</a></li><li class="breakAll">Cyclosporine 0.1% ophthalmic emulsion. US Food &amp; Drug Admnistration (FDA) approved product information. Revised 6/2021. US Food &amp; Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214965s000lbl.pdf (Accessed on August 13, 2021).</li><li><a class="nounderline abstract_t">Pucci N, Caputo R, di Grande L, et al. Tacrolimus vs. cyclosporine eyedrops in severe cyclosporine-resistant vernal keratoconjunctivitis: A randomized, comparative, double-blind, crossover study. Pediatr Allergy Immunol 2015; 26:256.</a></li><li><a class="nounderline abstract_t">Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N, et al. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol 2012; 30:177.</a></li><li><a class="nounderline abstract_t">Müller GG, José NK, de Castro RS. Topical tacrolimus 0.03% as sole therapy in vernal keratoconjunctivitis: a randomized double-masked study. Eye Contact Lens 2014; 40:79.</a></li><li><a class="nounderline abstract_t">Kumari R, Saha BC, Sinha BP, Mohan N. Tacrolimus versus Cyclosporine- Comparative Evaluation as First line drug in Vernal keratoconjuctivitis. Nepal J Ophthalmol 2017; 9:128.</a></li><li><a class="nounderline abstract_t">Müller EG, Santos MSD, Freitas D, et al. Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial. Arq Bras Oftalmol 2017; 80:154.</a></li><li><a class="nounderline abstract_t">Zanjani H, Aminifard MN, Ghafourian A, et al. Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2b Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study. Cornea 2017; 36:675.</a></li><li><a class="nounderline abstract_t">Kim SE, Nowak V, Quartilho A, et al. Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years. Cochrane Database Syst Rev 2020; 10:CD013298.</a></li><li><a class="nounderline abstract_t">Tesse R, Spadavecchia L, Fanelli P, et al. Treatment of severe vernal keratoconjunctivitis with 1% topical cyclosporine in an Italian cohort of 197 children. Pediatr Allergy Immunol 2010; 21:330.</a></li><li><a class="nounderline abstract_t">Gedik S, Akova YA, Gür S. Secondary bacterial keratitis associated with shield ulcer caused by vernal conjunctivitis. Cornea 2006; 25:974.</a></li><li><a class="nounderline abstract_t">Ozbek Z, Burakgazi AZ, Rapuano CJ. Rapid healing of vernal shield ulcer after surgical debridement: A case report. Cornea 2006; 25:472.</a></li><li><a class="nounderline abstract_t">Solomon A, Zamir E, Levartovsky S, Frucht-Pery J. Surgical management of corneal plaques in vernal keratoconjunctivitis: a clinicopathologic study. Cornea 2004; 23:608.</a></li><li><a class="nounderline abstract_t">Cetinkaya A, Akova YA, Dursun D, Pelit A. Topical cyclosporine in the management of shield ulcers. Cornea 2004; 23:194.</a></li><li><a class="nounderline abstract_t">Sharma A, Gupta R, Ram J, Gupta A. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J Ophthalmol 1997; 45:177.</a></li><li><a class="nounderline abstract_t">Kosrirukvongs P, Luengchaichawange C. Topical cyclosporine 0.5 per cent and preservative-free ketorolac tromethamine 0.5 per cent in vernal keratoconjunctivitis. J Med Assoc Thai 2004; 87:190.</a></li><li><a class="nounderline abstract_t">Uchio E, Itoh Y, Kadonosono K. Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis. Ophthalmologica 2007; 221:153.</a></li><li><a class="nounderline abstract_t">D'Angelo G, Lambiase A, Cortes M, et al. Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 2003; 241:192.</a></li><li><a class="nounderline abstract_t">Sud RN, Greval RS, Bajwa RS. Topical flurbiprofen therapy in vernal keratoconjunctivitis. Indian J Med Sci 1995; 49:205.</a></li><li><a class="nounderline abstract_t">Gupta S, Khurana AK, Ahluwalia BK, Gupta NC. Topical indomethacin for vernal keratoconjunctivitis. Acta Ophthalmol (Copenh) 1991; 69:95.</a></li><li><a class="nounderline abstract_t">Occasi F, Duse M, Nebbioso M, et al. Vernal keratoconjunctivitis treated with omalizumab: A case series. Pediatr Allergy Immunol 2017; 28:503.</a></li><li><a class="nounderline abstract_t">Sanchez J, Cardona R. An option in vernal keratoconjunctivitis? Allergol Immunopathol (Madr) 2012; 40:19.</a></li><li><a class="nounderline abstract_t">de Klerk TA, Sharma V, Arkwright PD, Biswas S. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. J AAPOS 2013; 17:305.</a></li><li><a class="nounderline abstract_t">Occasi F, Zicari AM, Petrarca L, et al. Vernal Keratoconjunctivitis and immune-mediated diseases: One unique way to symptom control? Pediatr Allergy Immunol 2015; 26:289.</a></li><li><a class="nounderline abstract_t">Heffler E, Picardi G, Liuzzo MT, et al. Omalizumab Treatment of Vernal Keratoconjunctivitis. JAMA Ophthalmol 2016; 134:461.</a></li></ol></div><div id="topicVersionRevision">Topic 5549 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18786127" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Vernal keratoconjunctivitis: a major review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18356259" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence of vernal keratoconjunctivitis: a rare disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10551301" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Vernal keratoconjunctivitis in a Stockholm ophthalmic centre--epidemiological, functional, and immunologic investigations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10857837" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14620434" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Vernal keratoconjunctivitis in Nigerians: 109 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19191180" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prospective, multicenter demographic and epidemiological study on vernal keratoconjunctivitis: a glimpse of ocular surface in Italian population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22963206" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : New insights into childhood Vernal keratoconjunctivitis-associated factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2606216" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Limbal vernal keratoconjunctivitis: clinical characteristics and immunoglobulin E expression compared with palpebral vernal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12052387" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Vernal keratoconjunctivitis: pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19638928" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A simple and rapid diagnostic algorithm for the detection of ocular allergic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620858" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Immune mechanisms in allergic eye diseases: what is new?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3262844" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : House dust mites and vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12063032" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Immunological characteristics of patients with vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1730830" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Conjunctival hyperresponsiveness to ocular histamine challenge in patients with vernal conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15629970" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Long eyelashes in a case series of 93 children with vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7443214" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Tear histamine levels in vernal conjunctivitis and other ocular inflammations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16538446" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Th1- and Th2-type cytokines in chronic ocular allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16776679" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7612563" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Collagen types I and III in giant papillae of vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21545429" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Histamine H4 receptors in normal conjunctiva and in vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15746957" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immunopathogenesis of conjunctival remodelling in vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12623809" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3195319" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Atopic conjunctivitis. A cytologic examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1782781" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Detection by brush cytology of mast cells and eosinophils in allergic and vernal conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17873585" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical grading of vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20382430" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Tailored approach to the treatment of vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425012" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Modern approach to managing vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9759796" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9645717" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12117082" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11558863" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19668750" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16245967" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16245967" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996516" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15117570" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A comparative trial of the safety and efficacy of 0.1 percent pemirolast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12946545" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17273679" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : [Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3140155" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Evaluation of topical cromolyn sodium in the treatment of vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10396195" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy of nedocromil 2% versus fluorometholone 0.1%: a randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10374055" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Atopic and vernal keratoconjunctivitis: a model for studying atopic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10890862" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9135403" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17588996" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7785747" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparative therapeutic studies with Tilavist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12931748" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Vernal keratoconjunctivitis in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15069427" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24008064" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : [Effectiveness of allergen immunotherapy in patients with vernal keratoconjuctivitis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17900694" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767456" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Vernal keratoconjunctivitis: Result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33819510" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy of medical treatments for vernal keratoconjunctivitis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1800929" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Topical cyclosporine in vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12269651" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2248328" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8306663" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Topical cyclosporin A in the treatment of anterior segment inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12376851" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : [Cyclosporin A 2% eyedrops in therapy of atopic and vernal keratoconjunctivitis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11399937" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21868078" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30593775" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis: The VEKTIS Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30593775" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis: The VEKTIS Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25712437" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Tacrolimus vs. cyclosporine eyedrops in severe cyclosporine-resistant vernal keratoconjunctivitis: A randomized, comparative, double-blind, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23156846" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24418865" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Topical tacrolimus 0.03% as sole therapy in vernal keratoconjunctivitis: a randomized double-masked study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29634701" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Tacrolimus versus Cyclosporine- Comparative Evaluation as First line drug in Vernal keratoconjuctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28832739" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28399035" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2b Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33084033" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19840298" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Treatment of severe vernal keratoconjunctivitis with 1% topical cyclosporine in an Italian cohort of 197 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17102679" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Secondary bacterial keratitis associated with shield ulcer caused by vernal conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16670489" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Rapid healing of vernal shield ulcer after surgical debridement: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15257001" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Surgical management of corneal plaques in vernal keratoconjunctivitis: a clinicopathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15075890" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Topical cyclosporine in the management of shield ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9475021" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15061303" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Topical cyclosporine 0.5 per cent and preservative-free ketorolac tromethamine 0.5 per cent in vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17440276" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12644942" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8906937" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Topical flurbiprofen therapy in vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2028777" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Topical indomethacin for vernal keratoconjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28543949" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Vernal keratoconjunctivitis treated with omalizumab: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : An option in vernal keratoconjunctivitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23607979" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25692810" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Vernal Keratoconjunctivitis and immune-mediated diseases: One unique way to symptom control?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26795360" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Omalizumab Treatment of Vernal Keratoconjunctivitis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
